Meeting Banner
Abstract #1121

Monitoring quantitative tumor blood volume in mouse brain under Bevacizumab by the RSST1-MRI method.

Michel Sarraf 1,2 , Flavien Caraguel 1 , Franois Berger 1 , Boudewijn Van Der Sanden 1 , and Hana Lahrech 1

1 CEA-CLINATEC, Grenoble, Isre, Rhne-Alpes, France, 2 Saint Joseph University, Beyrouth, Lebanon

Blood volume fraction (BVf) and vessel permeability have been shown to indicate anti-angiogenic therapy response at an early stage (before changes in tumor size appear). This study demonstrates the sensitivity of the RSST1-MRI method to quantify BVf, to detect the vasculature changes in U87 human glioblastoma cell (in mouse brain) at an early stage, after treatment with Bevacizumab, which is injected intravenously at a dose of 10 mg/kg (Student t-test: Pvalue <0.05). RSST1 is suitable to assess the effect of new anti-angiogenic therapies, and help physicians to take early decisions to stop, continue or change therapy strategies during treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here